Last reviewed · How we verify
Multiple Ascending Dose SC
At a glance
| Generic name | Multiple Ascending Dose SC |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma (PHASE1)
- A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) (PHASE1)
- Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults (PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults (PHASE1)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants. (PHASE1)
- First in Human Study in Subjects With Obesity, But Otherwise Healthy (PHASE1)
- First Time in Human Study of Long Acting VH4524184 Formulations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multiple Ascending Dose SC CI brief — competitive landscape report
- Multiple Ascending Dose SC updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI